Pascal Artru

10.4k total citations · 1 hit paper
132 papers, 3.7k citations indexed

About

Pascal Artru is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Pascal Artru has authored 132 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 38 papers in Surgery. Recurrent topics in Pascal Artru's work include Colorectal Cancer Treatments and Studies (67 papers), Pancreatic and Hepatic Oncology Research (41 papers) and Gastric Cancer Management and Outcomes (33 papers). Pascal Artru is often cited by papers focused on Colorectal Cancer Treatments and Studies (67 papers), Pancreatic and Hepatic Oncology Research (41 papers) and Gastric Cancer Management and Outcomes (33 papers). Pascal Artru collaborates with scholars based in France, Belgium and Canada. Pascal Artru's co-authors include Christophe Louvet, Thierry André, Pascal Hammel, F. Huguet, Benoist Chibaudel, Laurent Mineur, Aimery de Gramont, Olivier Bouché, Franck Bonnetain and May Mabro and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Pascal Artru

125 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations Pascal Hammel, F. Huguet et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Artru France	28	3.1k	1.4k	979	854	660	132	3.7k
Benoist Chibaudel France	28	2.9k 0.9×	1.3k 0.9×	724 0.7×	1.0k 1.2×	510 0.8×	157	3.7k
Nicola Personeni Italy	28	2.0k 0.7×	943 0.7×	568 0.6×	803 0.9×	1.1k 1.6×	89	3.1k
Guy van Hazel Australia	26	3.7k 1.2×	1.8k 1.3×	894 0.9×	942 1.1×	1.1k 1.7×	66	5.2k
E. Kettner Germany	16	2.6k 0.9×	1.0k 0.7×	647 0.7×	887 1.0×	192 0.3×	38	3.0k
Gabriele Luppi Italy	28	3.4k 1.1×	1.3k 0.9×	398 0.4×	1.7k 2.0×	360 0.5×	105	4.3k
Lawrence S. Blaszkowsky United States	37	3.5k 1.1×	1.8k 1.3×	1.1k 1.1×	1.6k 1.8×	1.0k 1.5×	182	5.5k
Elizabeth Poplin United States	24	2.2k 0.7×	1.2k 0.8×	485 0.5×	721 0.8×	281 0.4×	80	3.2k
Lipika Goyal United States	31	2.5k 0.8×	1.4k 0.9×	854 0.9×	2.3k 2.7×	1.3k 1.9×	185	5.1k
Gérard Lledo France	27	5.8k 1.9×	2.3k 1.6×	652 0.7×	1.7k 2.0×	1.6k 2.4×	101	6.5k
Karsten Ridwelski Germany	20	3.9k 1.3×	1.8k 1.3×	1.0k 1.0×	2.1k 2.5×	424 0.6×	109	4.8k

Countries citing papers authored by Pascal Artru

Since Specialization

Citations

This map shows the geographic impact of Pascal Artru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Artru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Artru more than expected).

Fields of papers citing papers by Pascal Artru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Artru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Artru. The network helps show where Pascal Artru may publish in the future.

Co-authorship network of co-authors of Pascal Artru

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Artru. A scholar is included among the top collaborators of Pascal Artru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Artru. Pascal Artru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

François, Éric, Nicolas Magné, Rabia Boulahssass, et al.. (2024). Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment. Radiotherapy and Oncology. 193. 110144–110144.

Dupré, Aurélien, Pascal Artru, Antoine Drouillard, et al.. (2024). Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study. Digestive and Liver Disease. 56(9). 1605–1613.

Meurisse, Aurélia, Pascal Artru, Thierry Lecomte, et al.. (2024). 517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study. Annals of Oncology. 35. S438–S438. 1 indexed citations

Gallois, Claire, Édouard Auclin, Elisabeth Bergen, et al.. (2023). 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study. Annals of Oncology. 34. S446–S446. 4 indexed citations

Hautefeuille, Vincent, Édouard Auclin, Astrid Lièvre, et al.. (2022). Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer. 126(10). 1394–1400. 5 indexed citations

Roth, Gaël S., Yohan Fayet, Françoise Ducimetière, et al.. (2022). Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. Cancers. 14(21). 5413–5413. 1 indexed citations

Hautefeuille, Vincent, Louis de Mestier, Clélia Coutzac, et al.. (2022). Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study. International Journal of Cancer. 152(9). 1894–1902. 2 indexed citations

Benoist, Stéphane, Patrick Devos, Stéphanie Truant, et al.. (2022). Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study. World Journal of Surgical Oncology. 20(1). 131–131. 15 indexed citations

Pernot, Simon, Olivier Pellerin, Pascal Artru, et al.. (2020). Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. British Journal of Cancer. 123(4). 518–524. 19 indexed citations

10.

Brouquet, Antoine, Jean‐Baptiste Bachet, F. Huguet, et al.. (2020). NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial). BMC Cancer. 20(1). 485–485. 15 indexed citations

11.

Gallois, Claire, Pascal Artru, Astrid Lièvre, et al.. (2019). Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. European Journal of Cancer. 119. 35–43. 28 indexed citations

12.

Bennouna, Jaafar, Thierry André, L. Campion, et al.. (2018). Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial. Clinical Colorectal Cancer. 18(1). e69–e73. 14 indexed citations

13.

Zaanan, Aziz, Emmanuelle Samalin, Christophe Louvet, et al.. (2017). PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma. Annals of Oncology. 28. v265–v265. 4 indexed citations

14.

Artru, Pascal, Estelle Le Pabic, Marc Pracht, et al.. (2017). Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease. 49(6). 692–696. 23 indexed citations

15.

Zaanan, Aziz, Isabelle Trouilloud, Mélanie Gauthier, et al.. (2014). FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer. 14(1). 441–441. 27 indexed citations

16.

Chibaudel, Benoist, Frédérique Maindrault‐Gœbel, Gérard Lledo, et al.. (2009). Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical Oncology. 27(34). 5727–5733. 262 indexed citations

17.

Dahan, Laëtitia, D Atlan, Olivier Bouché, et al.. (2005). Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen?. Gastroentérologie Clinique et Biologique. 29(1). 11–15. 13 indexed citations

18.

Maindrault-Gœbel, F., Christophe Tournigand, Thierry André, et al.. (2004). Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Annals of Oncology. 15(8). 1210–1214. 70 indexed citations

19.

Taı̈eb, Julien, Emmanuel Mitry, Valérie Boige, et al.. (2002). Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Annals of Oncology. 13(8). 1192–1196. 78 indexed citations

20.

Gramont, Aimery de, Christophe Louvet, Thierry André, et al.. (2000). Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Annals of Oncology. 11(11). 1477–1483. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact